PG 3113
Latest Information Update: 13 Dec 1995
At a glance
- Originator Pharmagenesis
- Class Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection
Most Recent Events
- 01 Sep 1995 Discontinued-Preclinical for Rheumatoid arthritis in USA (Unknown route)
- 01 Sep 1995 Discontinued-Preclinical for Systemic lupus erythematosus in USA (Unknown route)
- 01 Sep 1995 Discontinued-Preclinical for Transplant rejection in USA (Unknown route)